Patents by Inventor Keith Duncan

Keith Duncan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of Ocular Surface Disorders by Increasing Conjunctival Vascular Permeability
    Publication number: 20110217262
    Abstract: A method of treating an ocular surface disorder in a subject in need of such treatment is provided. The method includes exposing conjunctival tissue of the subject to an effective amount of a vasopermeability agent that increases conjunctival vascular permeability. In some embodiments, the agent is a nitric oxide donor, which may be in a sustained release form. A method of screening a substance for treating an ocular surface disorder is also provided.
    Type: Application
    Filed: March 7, 2011
    Publication date: September 8, 2011
    Inventors: Julia A. Kornfield, Robert H. Grubbs, Choon Woo Lee, Daniel Schwartz, Phoebe Lin, Keith Duncan
  • Treatment for dark adaptation
    Publication number: 20050282750
    Abstract: The present invention addresses the treatment of age-related macular degeneration using regulation of pathogenic mechanisms similar to atherosclerosis. In further specific embodiments, compositions that increase reverse cholesterol transport are utilized as therapeutic targets for age-related macular degeneration. In a specific embodiment, the lipid content of the retinal pigment epithelium, and/or Bruch's membrane is reduced by delivering Apolipoprotein A1, particularly a mimetic peptide.
    Type: Application
    Filed: February 10, 2005
    Publication date: December 22, 2005
    Inventors: Daniel Schwartz, Keith Duncan, Kathy Bailey, John Kane, Brian Ishida
  • Treatment for age-related macular degeneration (AMD)
    Publication number: 20030162758
    Abstract: The present invention addresses the treatment of age-related macular degeneration using regulation of pathogenic mechanisms similar to atherosclerosis. In further specific embodiments, reverse cholesterol transport components, such as transporters and HDL fractions, are utilized as diagnostic and therapeutic targets for age-related macular degeneration. In a specific embodiment, the lipid content of the retinal pigment epithelium, and/or Bruch's membrane is reduced.
    Type: Application
    Filed: December 6, 2002
    Publication date: August 28, 2003
    Inventors: Daniel M. Schwartz, Keith Duncan, Kathy Bailey, John Kane, Brian Ishida